| Expression pattern: |
UP |
| Associated gene: |
EGFR |
| Associated microRNA: |
miR-665 |
| Biological function: |
CircMYBL2 promotes paclitaxel resistance, cervical cancer cell proliferation and colony formation, enhances tumor growth in vivo, and suppresses paclitaxel-induced apoptosis and cytotoxicity. |
| Molecular mechanism: |
CircMYBL2 functions as a ceRNA by sponging miR-665, thereby upregulating EGFR and promoting paclitaxel resistance and malignant behaviors in cervical cancer cells. |
| Biological pathway or process: |
drug resistance (promotes); chemoresistance (promotes); proliferation (promotes); apoptosis (inhibits); ceRNA regulation (promotes); EGFR (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RNase R Treatment; RT-qPCR; Clinical Sample Validation; Nuclear-Cytoplasmic Fractionation; Luciferase Reporter Assay; Transfection; MTT; EdU Staining; Colony Formation Assay; Annexin V/PI Flow Cytometry; Western Blot; IHC (Immunohistochemistry); In Vivo Animal Model; Bioinformatics Analysis |
| Clinical significance: |
CircMYBL2 may serve as a novel biomarker and therapeutic target for PTX-resistant cervical cancer. |
| Description: |
CircMYBL2 is upregulated in cervical cancer, with higher expression in PTX-resistant tissues and cells. It promotes paclitaxel resistance, tumor growth, and malignant cellular behaviors by sponging miR-665 and thereby increasing EGFR expression, suggesting potential value as a biomarker and therapeutic target for PTX-resistant cervical cancer. |
| Confidence score: |
0.7859 |